Short-acting GHRH analog (modified GRF 1–29) studied for pulsatile GH-axis signaling.
⚠ For research use only · Not for human use · Not FDA approved
A short research-handling guide for CJC-1295 (no DAC). For laboratory and research use only.
Short-acting GHRH analog (modified GRF 1–29) studied for pulsatile GH-axis signaling.
CJC-1295 (no DAC) is supplied as a lyophilized (freeze-dried) powder. Reconstitute it before research use. Recommended diluent: bacteriostatic water.
Example: 2 ml of diluent in this 5 mg vial gives 2,500 mcg/ml. A 100 mcg research amount is then 0.04 ml (4 units on a U-100 syringe) — about 50 doses per vial.
Most commonly referenced in published research at 100–200 mcg, once daily. Reference only — not a dosing instruction.
Keep lyophilized vials frozen and out of light. Once reconstituted, refrigerate (2–8 °C) and use within a few weeks. Always use sterile technique.
For laboratory and research use only. Not for human or veterinary use, food, or drug applications.